We thank Rüschoff et al. for their interest in our work 1 and believe that an ongoing conversation regarding the significance of tumors with "unusual staining" from mismatch repair (MMR) immunohistochemistry (IHC) will be critical to improving the outcomes for patients with endometrial cancer. Algorithms such as the one proposed by the authors 2 can help to refine MMR/microsatellite instability (MSI) testing results and illustrate that multiple testing strategies (i.e., IHC, MSI, and next-generation sequencing) are likely to be needed and can be complementary.